Technology Bundle ID

Recombinant Polypeptides for Clinical Detection of Taenia solium and Diagnosis of Cysticercosis

Linked ID
Lead Inventors
Victor Tsang (CDC)
Kathy Hancock (CDC)
Patricia Wilkins (CDC)
Ryan Greene (CDC)
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
CDC scientists have developed synthetic/recombinant polypeptides that can be used for the creation of inexpensive, high-quality cysticercosis diagnostic assays. Taenia solium is a species of pathogenic tapeworm. Intestinal infection with this parasite is referred to as taeniasis and it is acquired by ingestion of T. solium cysticerci found in raw and undercooked pork, or food contaminated with human or porcine excrement. Many infections are asymptomatic, but infection may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis is the formation of cysticerci in various body tissues resulting from the migration of the T. solium larvae out of the intestine. Although infection with T. solium is itself not dangerous, cysticercosis can be fatal. In the present invention, specific antigen encoding nucleotide sequences have been cloned; assays based on the produced antigens may be useful for improvements over the existing Western blot diagnostic method for identifying individuals with cysticercosis. Additionally, these polypeptides may have applications in developing vaccines and therapeutics to prevent taeniasis.
Commercial Applications
  • Diagnosis of T. solium infection and confirmation of cysticercosis
  • Zoonotic disease research and surveillance
  • Public health monitoring programs
  • Livestock health and food-source monitoring
  • Therapeutics/vaccine development
Competitive Advantages
  • May provide a rapid, accurate, sensitive and safe alternative to current radiologic, Western blot and biopsy diagnostic methods
  • Can be easily formatted as a simple-to-use assay kit for FAST-ELISA
  • Cost-effective, and quite useful for developing regions of the world

Request More Info

Licensing Contact: